Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy: Treatment Patterns From the PROXIMA Prospective Registry
Purpose: There is a major clinical need to devise an optimal treatment sequence for the multiple therapy options available for patients with metastatic castration-resistant prostate cancer (mCRPC). In the absence of prospective clinical trials, sequencing information can be derived from large, real-...
Main Authors: | Hideyuki Akaza, Giuseppe Procopio, Choosak Pripatnanont, Gaetano Facchini, Sergio Fava, Duncan Wheatley, Kwong Chuen Leung, Mohammad Butt, Alberto Silva, Liliana Castillo, Vasilios Karavasilis, Ayse Ӧzatılgan, Simon Hitier, Evelyne B. Ecstein-Fraisse, Mustafa Ӧzgüroḡlu |
---|---|
Format: | Article |
Language: | English |
Published: |
American Society of Clinical Oncology
2018-09-01
|
Series: | Journal of Global Oncology |
Online Access: | http://ascopubs.org/doi/10.1200/JGO.18.00009 |
Similar Items
-
Effect of Baseline Characteristics on Cabazitaxel Treatment Duration in Patients with Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of the Compassionate Use/Expanded Access Programs and CAPRISTANA Registry
by: Zafar Malik, et al.
Published: (2020-04-01) -
Post-docetaxel therapy in castration resistant prostate cancer – the forest is growing in the desert
by: Amelia Altavilla, et al.
Published: (2012-06-01) -
Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
by: Filippo Francini, et al.
Published: (2011-01-01) -
Docetaxel in very elderly men with metastatic castration-resistant prostate cancer
by: Hui-Li Wong, et al.
Published: (2015-06-01) -
Clinical outcomes in castration resistant prostate cancer patients treated with docetaxel
by: Shian-Shiang Wang, et al.
Published: (2016-06-01)